当前位置: X-MOL 学术Clin. Exp. Allergy › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Real-word experience with Mepolizumab: Does it deliver what it has promised?
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2020-04-14 , DOI: 10.1111/cea.13601
Florence Schleich 1, 2 , Sophie Graff 1, 2 , Haleh Nekoee 3 , Catherine Moermans 1, 2 , Monique Henket 1, 2 , Carole Sanchez 1, 2 , Virginie Paulus 1, 2 , Françoise Guissard 1, 2 , Anne-Françoise Donneau 3 , Renaud Louis 1, 2
Affiliation  

Randomized control trials performed in selected populations of severe eosinophilic asthmatics have shown that mepolizumab, an anti‐IL5 therapy, was able to reduce exacerbations and OCS maintenance dose and in some studies, to improve asthma control and lung function.

中文翻译:

Mepolizumab 的真实体验:它是否兑现了它的承诺?

在选定的重度嗜酸性粒细胞哮喘患者人群中进行的随机对照试验表明,美泊利单抗(一种抗 IL5 疗法)能够减少急性发作和 OCS 维持剂量,并且在一些研究中,可以改善哮喘控制和肺功能。
更新日期:2020-04-14
down
wechat
bug